| Mr Tim J Gienger, LICSW | |
|
1237 W Divide Ave, Ste 5, Bismarck, ND 58501-1208 | |
| (701) 328-8888 | |
| (701) 328-8900 |
| Full Name | Mr Tim J Gienger |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 1237 W Divide Ave, Bismarck, North Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245291525 | NPI | - | NPPES |
| 19161 | Medicaid | ND | |
| 26592 | Other | ND | BLUE CROSS BLUE SHIELD ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 3637 (North Dakota) | Primary |
| Entity Name | West Central Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226713 PECOS PAC ID: 6002801107 Enrollment ID: O20040419000160 |
News Archive
A novel study in twins found that exposure to trichloroethylene (TCE)—a hazardous organic contaminant found in soil, groundwater, and air—is significantly associated with increased risk of Parkinson's disease (PD). Possibility of developing this neurodegenerative disease is also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) exposure according to the study appearing today in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association and Child Neurology Society.
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Chris Endean of the GAVI Alliance writes ahead of the GAVI Partners Forum in a CNN opinion piece about efforts to vaccinate members of the Maasai tribes in Tanzania's Arusha National Park. Noting Maasai tribes are "constantly on the move searching for water and fresh pasture for their cattle," he describes "severe logistical challenges" health workers face when trying to reach their patients and notes."
NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Tim J Gienger, LICSW 1237 W Divide Ave, Ste 5, Bismarck, ND 58501-1208 Ph: (701) 328-8888 | Mr Tim J Gienger, LICSW 1237 W Divide Ave, Ste 5, Bismarck, ND 58501-1208 Ph: (701) 328-8888 |
News Archive
A novel study in twins found that exposure to trichloroethylene (TCE)—a hazardous organic contaminant found in soil, groundwater, and air—is significantly associated with increased risk of Parkinson's disease (PD). Possibility of developing this neurodegenerative disease is also linked to perchloroethylene (PERC) and carbon tetrachloride (CCI4) exposure according to the study appearing today in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association and Child Neurology Society.
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Chris Endean of the GAVI Alliance writes ahead of the GAVI Partners Forum in a CNN opinion piece about efforts to vaccinate members of the Maasai tribes in Tanzania's Arusha National Park. Noting Maasai tribes are "constantly on the move searching for water and fresh pasture for their cattle," he describes "severe logistical challenges" health workers face when trying to reach their patients and notes."
NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.
› Verified 5 days ago
Brooke Leanne Joritz, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2700 State St Ste F, Bismarck, ND 58503 Phone: 701-895-4685 | |
Kellie Hoffman, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 619 Riverwood Dr Ste 105, Bismarck, ND 58504 Phone: 701-224-9751 | |
Jackie Marie Lelm, LICSW, MSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1237 W Divide Ave, Ste 5, Bismarck, ND 58501 Phone: 701-328-8843 Fax: 701-328-8900 | |
Darla J Stafford, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1800 E Interstate Ave Ste B, Bismarck, ND 58503 Phone: 701-323-6543 Fax: 701-323-5492 | |
Elisabeth Oldham, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1310 E Main Ave, Bismarck, ND 58501 Phone: 701-530-7195 | |
Debra M. Bosch, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1701 Burnt Boat Dr, Second Floor, Bismarck, ND 58503 Phone: 701-323-0924 Fax: 701-323-0935 | |
Nikki Marie Mundahl, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 315 N 11th St, Bismarck, ND 58501 Phone: 218-329-7097 |